POST Online Media Lite Edition


Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes

Staff writer |
Sun Pharma and AstraZeneca Pharma India announced a partnership for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India.

Dapagliflozin is AstraZeneca India’s leading diabetes medicine. Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra.

AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market and distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name Oxramet, following regulatory approval.

AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin.

Diabetes is estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide. By 2040, this will rise to 642 million and Type 2 is the most common form of diabetes.

What to read next

AstraZeneca and PatientsLikeMe in global research collaboration
AstraZeneca sells Crohn's disease and ulcerative colitis medicine rights
Bristol-Myers Squibb to sell diabetes business